BAXTER INTERNATIONAL INC.
Net Sales by Segment
(unaudited, in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Years Ended December 31, | | | | |
| | | | | Reported Growth | | Constant Currency Growth | | | | | |
| 2020 | 2019 | 2018 | | 2020 | 2019 | | 2020 | 2019 | | | | | |
Net sales by segment: | | | | | | | | | | | | | | |
Americas | $ | 6,321 | | $ | 6,306 | | $ | 6,156 | | | 0 | % | 2 | % | | 2 | % | 4 | % | | | | | |
EMEA | 2,877 | | 2,756 | | 2,741 | | | 4 | % | 1 | % | | 4 | % | 5 | % | | | | | |
APAC | 2,475 | | 2,300 | | 2,202 | | | 8 | % | 4 | % | | 7 | % | 8 | % | | | | | |
Total net sales | $ | 11,673 | | $ | 11,362 | | $ | 11,099 | | | 3 | % | 2 | % | | 3 | % | 5 | % | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended December 31, | | | | |
| | | | | Reported Growth | | Constant Currency Growth | | | | | |
| 2020 | 2019 | 2018 | | 2020 | 2019 | | 2020 | 2019 | | | | | |
Net sales by segment: | | | | | | | | | | | | | | |
Americas | $ | 1,681 | | $ | 1,685 | | $ | 1,551 | | | (0) | % | 9 | % | | 1 | % | 9 | % | | | | | |
EMEA | 800 | | 736 | | 707 | | | 9 | % | 4 | % | | 4 | % | 6 | % | | | | | |
APAC | 700 | | 618 | | 575 | | | 13 | % | 7 | % | | 8 | % | 9 | % | | | | | |
Total net sales | $ | 3,181 | | $ | 3,039 | | $ | 2,833 | | | 5 | % | 7 | % | | 3 | % | 8 | % | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended September 30, | | | | |
| | | | | Reported Growth | | Constant Currency Growth | | | | | |
| 2020 | 2019 | 2018 | | 2020 | 2019 | | 2020 | 2019 | | | | | |
Net sales by segment: | | | | | | | | | | | | | | |
Americas | $ | 1,606 | | $ | 1,585 | | $ | 1,547 | | | 1 | % | 2 | % | | 3 | % | 4 | % | | | | | |
EMEA | 720 | | 679 | | 657 | | | 6 | % | 3 | % | | 3 | % | 7 | % | | | | | |
APAC | 646 | | 587 | | 557 | | | 10 | % | 5 | % | | 7 | % | 8 | % | | | | | |
Total net sales | $ | 2,972 | | $ | 2,851 | | $ | 2,761 | | | 4 | % | 3 | % | | 4 | % | 5 | % | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended June 30, | | | | |
| | | | | Reported Growth | | Constant Currency Growth | | | | | |
| 2020 | 2019 | 2018 | | 2020 | 2019 | | 2020 | 2019 | | | | | |
Net sales by segment: | | | | | | | | | | | | | | |
Americas | $ | 1,469 | | $ | 1,577 | | $ | 1,568 | | | (7) | % | 1 | % | | (4) | % | 2 | % | | | | | |
EMEA | 669 | | 684 | | 691 | | | (2) | % | (1) | % | | 0 | % | 5 | % | | | | | |
APAC | 580 | | 573 | | 554 | | | 1 | % | 3 | % | | 5 | % | 9 | % | | | | | |
Total net sales | $ | 2,718 | | $ | 2,834 | | $ | 2,813 | | | (4) | % | 1 | % | | (1) | % | 4 | % | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended March 31, | | | | |
| | | | | Reported Growth | | Constant Currency Growth | | | | | |
| 2020 | 2019 | 2018 | | 2020 | 2019 | | 2020 | 2019 | | | | | |
Net sales by segment: | | | | | | | | | | | | | | |
Americas | $ | 1,565 | | $ | 1,459 | | $ | 1,490 | | | 7 | % | (2) | % | | 8 | % | (0) | % | | | | | |
EMEA | 688 | | 657 | | 686 | | | 5 | % | (4) | % | | 8 | % | 3 | % | | | | | |
APAC | 549 | | 522 | | 516 | | | 5 | % | 1 | % | | 9 | % | 7 | % | | | | | |
Total net sales | $ | 2,802 | | $ | 2,638 | | $ | 2,692 | | | 6 | % | (2) | % | | 8 | % | 2 | % | | | | | |
BAXTER INTERNATIONAL INC.
Operating Income by Segment
(unaudited, in millions)
| | | | | | | | | | | | | | | | |
| Years Ended December 31, | | | | |
| 2020 | 2019 | 2018 | | | | | |
Operating income by segment | | | | | | | | |
Americas | $ | 2,389 | | $ | 2,499 | | $ | 2,533 | | | | | | |
EMEA | 523 | | 527 | | 544 | | | | | | |
APAC | 591 | | 549 | | 532 | | | | | | |
Total segment operating income | 3,503 | | 3,575 | | 3,609 | | | | | | |
Corporate and other | (1,887) | | (1,803) | | (2,025) | | | | | | |
Total operating income | $ | 1,616 | | $ | 1,772 | | $ | 1,584 | | | | | | |
| | | | | | | | | | | | | | | | |
| Quarters Ended December 31, | | | | |
| 2020 | 2019 | 2018 | | | | | |
Operating income by segment | | | | | | | | |
Americas | $ | 663 | | $ | 688 | | $ | 638 | | | | | | |
EMEA | 159 | | 158 | | 155 | | | | | | |
APAC | 159 | | 155 | | 149 | | | | | | |
Total segment operating income | 981 | | 1,001 | | 942 | | | | | | |
Corporate and other | (575) | | (465) | | (551) | | | | | | |
Total operating income | $ | 406 | | $ | 536 | | $ | 391 | | | | | | |
| | | | | | | | | | | | | | | | |
| Quarters Ended September 30, | | | | |
| 2020 | 2019 | 2018 | | | | | |
Operating income by segment | | | | | | | | |
Americas | $ | 611 | | $ | 625 | | $ | 651 | | | | | | |
EMEA | 126 | | 132 | | 137 | | | | | | |
APAC | 161 | | 138 | | 137 | | | | | | |
Total segment operating income | 898 | | 895 | | 925 | | | | | | |
Corporate and other | (428) | | (392) | | (543) | | | | | | |
Total operating income | $ | 470 | | $ | 503 | | $ | 382 | | | | | | |
| | | | | | | | | | | | | | | | |
| Quarters Ended June 30, | | | | |
| 2020 | 2019 | 2018 | | | | | |
Operating income by segment | | | | | | | | |
Americas | $ | 527 | | $ | 617 | | $ | 648 | | | | | | |
EMEA | 121 | | 124 | | 130 | | | | | | |
APAC | 143 | | 136 | | 131 | | | | | | |
Total segment operating income | 791 | | 877 | | 909 | | | | | | |
Corporate and other | (460) | | (527) | | (532) | | | | | | |
Total operating income | $ | 331 | | $ | 350 | | $ | 377 | | | | | | |
| | | | | | | | | | | | | | | | |
| Quarters Ended March 31, | | | | |
| 2020 | 2019 | 2018 | | | | | |
Operating income by segment | | | | | | | | |
Americas | $ | 588 | | $ | 569 | | $ | 596 | | | | | | |
EMEA | 117 | | 113 | | 122 | | | | | | |
APAC | 128 | | 120 | | 115 | | | | | | |
Total segment operating income | 833 | | 802 | | 833 | | | | | | |
Corporate and other | (424) | | (419) | | (399) | | | | | | |
Total operating income | $ | 409 | | $ | 383 | | $ | 434 | | | | | | |
BAXTER INTERNATIONAL INC.
Net Sales by Product Category
(unaudited, in millions)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Years Ended December 31, |
| | | | | | | | | | | | | Reported Growth | | Constant Currency Growth |
| 2020 | | 2019 | | 2018 | | 2020 | | 2019 | | 2020 | | 2019 |
| U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total |
Net sales by product category: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Renal Care | $ | 848 | | $ | 2,909 | | $ | 3,757 | | | $ | 791 | | $ | 2,848 | | $ | 3,639 | | | $ | 816 | | $ | 2,835 | | $ | 3,651 | | | 7 | % | 2 | % | 3 | % | | (3) | % | 0 | % | (0) | % | | 7 | % | 3 | % | 4 | % | | (3) | % | 5 | % | 3 | % |
Medication Delivery | 1,738 | | 953 | | 2,691 | | | 1,762 | | 977 | | 2,739 | | | 1,652 | | 974 | | 2,626 | | | (1) | % | (2) | % | (2) | % | | 7 | % | 0 | % | 4 | % | | (1) | % | (1) | % | (1) | % | | 7 | % | 5 | % | 6 | % |
Pharmaceuticals | 849 | | 1,249 | | 2,098 | | | 904 | | 1,215 | | 2,119 | | | 976 | | 1,091 | | 2,067 | | | (6) | % | 3 | % | (1) | % | | (7) | % | 11 | % | 3 | % | | (6) | % | 3 | % | (1) | % | | (7) | % | 17 | % | 5 | % |
Clinical Nutrition | 330 | | 580 | | 910 | | | 308 | | 552 | | 860 | | | 313 | | 554 | | 867 | | | 7 | % | 5 | % | 6 | % | | (2) | % | (0) | % | (1) | % | | 7 | % | 5 | % | 6 | % | | (2) | % | 4 | % | 2 | % |
Advanced Surgery | 516 | | 370 | | 886 | | | 533 | | 342 | | 875 | | | 465 | | 332 | | 797 | | | (3) | % | 8 | % | 1 | % | | 15 | % | 3 | % | 10 | % | | (3) | % | 8 | % | 1 | % | | 15 | % | 8 | % | 12 | % |
Acute Therapies | 286 | | 454 | | 740 | | | 184 | | 351 | | 535 | | | 174 | | 341 | | 515 | | | 55 | % | 29 | % | 38 | % | | 6 | % | 3 | % | 4 | % | | 55 | % | 30 | % | 39 | % | | 6 | % | 8 | % | 7 | % |
BioPharma Solutions | 234 | | 252 | | 486 | | | 257 | | 212 | | 469 | | | 244 | | 205 | | 449 | | | (9) | % | 19 | % | 4 | % | | 5 | % | 3 | % | 4 | % | | (9) | % | 17 | % | 3 | % | | 5 | % | 9 | % | 7 | % |
Other | 77 | | 28 | | 105 | | | 87 | | 39 | | 126 | | | 83 | | 44 | | 127 | | | (11) | % | (28) | % | (17) | % | | 5 | % | (11) | % | (1) | % | | (11) | % | (28) | % | (17) | % | | 5 | % | (9) | % | 0 | % |
Total Baxter | $ | 4,878 | | $ | 6,795 | | $ | 11,673 | | | $ | 4,826 | | $ | 6,536 | | $ | 11,362 | | | $ | 4,723 | | $ | 6,376 | | $ | 11,099 | | | 1 | % | 4 | % | 3 | % | | 2 | % | 3 | % | 2 | % | | 1 | % | 5 | % | 3 | % | | 2 | % | 7 | % | 5 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended December 31, |
| | | | | | | | | | | | | Reported Growth | | Constant Currency Growth |
| 2020 | | 2019 | | 2018 | | 2020 | | 2019 | | 2020 | | 2019 |
| U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total |
Net sales by product category: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Renal Care | $ | 219 | | $ | 794 | | $ | 1,013 | | | $ | 204 | | $ | 756 | | $ | 960 | | | $ | 207 | | $ | 744 | | $ | 951 | | | 7 | % | 5 | % | 6 | % | | (1) | % | 2 | % | 1 | % | | 7 | % | 3 | % | 4 | % | | (1) | % | 3 | % | 2 | % |
Medication Delivery | 476 | | 267 | | 743 | | | 495 | | 261 | | 756 | | | 401 | | 248 | | 649 | | | (4) | % | 2 | % | (2) | % | | 23 | % | 5 | % | 16 | % | | (4) | % | 1 | % | (2) | % | | 23 | % | 8 | % | 17 | % |
Pharmaceuticals | 212 | | 350 | | 562 | | | 240 | | 330 | | 570 | | | 241 | | 288 | | 529 | | | (12) | % | 6 | % | (1) | % | | (0) | % | 15 | % | 8 | % | | (12) | % | 2 | % | (4) | % | | (0) | % | 17 | % | 9 | % |
Clinical Nutrition | 89 | | 154 | | 243 | | | 80 | | 149 | | 229 | | | 75 | | 137 | | 212 | | | 11 | % | 3 | % | 6 | % | | 7 | % | 9 | % | 8 | % | | 11 | % | 1 | % | 4 | % | | 7 | % | 11 | % | 9 | % |
Advanced Surgery | 147 | | 112 | | 259 | | | 137 | | 93 | | 230 | | | 127 | | 86 | | 213 | | | 7 | % | 20 | % | 13 | % | | 8 | % | 8 | % | 8 | % | | 7 | % | 15 | % | 10 | % | | 8 | % | 12 | % | 9 | % |
Acute Therapies | 82 | | 139 | | 221 | | | 48 | | 96 | | 144 | | | 45 | | 91 | | 136 | | | 71 | % | 45 | % | 53 | % | | 7 | % | 5 | % | 6 | % | | 71 | % | 40 | % | 50 | % | | 7 | % | 8 | % | 7 | % |
BioPharma Solutions | 48 | | 67 | | 115 | | | 64 | | 53 | | 117 | | | 53 | | 59 | | 112 | | | (25) | % | 26 | % | (2) | % | | 21 | % | (10) | % | 4 | % | | (25) | % | 19 | % | (5) | % | | 21 | % | (7) | % | 6 | % |
Other | 17 | | 8 | | 25 | | | 21 | | 12 | | 33 | | | 23 | | 8 | | 31 | | | (19) | % | (33) | % | (24) | % | | (9) | % | 50 | % | 6 | % | | (19) | % | (50) | % | (30) | % | | (9) | % | 38 | % | 3 | % |
Total Baxter | $ | 1,290 | | $ | 1,891 | | $ | 3,181 | | | $ | 1,289 | | $ | 1,750 | | $ | 3,039 | | | $ | 1,172 | | $ | 1,661 | | $ | 2,833 | | | 0 | % | 8 | % | 5 | % | | 10 | % | 5 | % | 7 | % | | 0 | % | 5 | % | 3 | % | | 10 | % | 7 | % | 8 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended September 30, |
| | | | | | | | | | | | | Reported Growth | | Constant Currency Growth |
| 2020 | | 2019 | | 2018 | | 2020 | | 2019 | | 2020 | | 2019 |
| U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total |
Net sales by product category: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Renal Care | $ | 216 | | $ | 739 | | $ | 955 | | | $ | 199 | | $ | 719 | | $ | 918 | | | $ | 209 | | $ | 698 | | $ | 907 | | | 9 | % | 3 | % | 4 | % | | (5) | % | 3 | % | 1 | % | | 9 | % | 3 | % | 4 | % | | (5) | % | 6 | % | 4 | % |
Medication Delivery | 419 | | 246 | | 665 | | | 446 | | 240 | | 686 | | | 405 | | 234 | | 639 | | | (6) | % | 3 | % | (3) | % | | 10 | % | 3 | % | 7 | % | | (6) | % | 3 | % | (3) | % | | 10 | % | 6 | % | 9 | % |
Pharmaceuticals | 209 | | 330 | | 539 | | | 212 | | 304 | | 516 | | | 243 | | 278 | | 521 | | | (1) | % | 9 | % | 4 | % | | (13) | % | 9 | % | (1) | % | | (1) | % | 5 | % | 3 | % | | (13) | % | 14 | % | 2 | % |
Clinical Nutrition | 87 | | 147 | | 234 | | | 77 | | 139 | | 216 | | | 81 | | 137 | | 218 | | | 13 | % | 6 | % | 8 | % | | (5) | % | 1 | % | (1) | % | | 13 | % | 1 | % | 6 | % | | (5) | % | 6 | % | 2 | % |
Advanced Surgery | 138 | | 97 | | 235 | | | 134 | | 82 | | 216 | | | 122 | | 77 | | 199 | | | 3 | % | 18 | % | 9 | % | | 10 | % | 6 | % | 9 | % | | 3 | % | 17 | % | 8 | % | | 10 | % | 10 | % | 10 | % |
Acute Therapies | 72 | | 105 | | 177 | | | 44 | | 86 | | 130 | | | 41 | | 81 | | 122 | | | 64 | % | 22 | % | 36 | % | | 7 | % | 6 | % | 7 | % | | 64 | % | 21 | % | 35 | % | | 7 | % | 10 | % | 9 | % |
BioPharma Solutions | 84 | | 57 | | 141 | | | 89 | | 51 | | 140 | | | 74 | | 50 | | 124 | | | (6) | % | 12 | % | 1 | % | | 20 | % | 2 | % | 13 | % | | (6) | % | 4 | % | (2) | % | | 20 | % | 6 | % | 15 | % |
Other | 19 | | 7 | | 26 | | | 23 | | 6 | | 29 | | | 19 | | 12 | | 31 | | | (17) | % | 17 | % | (10) | % | | 21 | % | (50) | % | (6) | % | | (17) | % | 50 | % | (3) | % | | 21 | % | (42) | % | (3) | % |
Total Baxter | $ | 1,244 | | $ | 1,728 | | $ | 2,972 | | | $ | 1,224 | | $ | 1,627 | | $ | 2,851 | | | $ | 1,194 | | $ | 1,567 | | $ | 2,761 | | | 2 | % | 6 | % | 4 | % | | 3 | % | 4 | % | 3 | % | | 2 | % | 5 | % | 4 | % | | 3 | % | 8 | % | 5 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended June 30, |
| | | | | | | | | | | | | Reported Growth | | Constant Currency Growth |
| 2020 | | 2019 | | 2018 | | 2020 | | 2019 | | 2020 | | 2019 |
| U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total |
Net sales by product category: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Renal Care | $ | 209 | | $ | 710 | | $ | 919 | | | $ | 196 | | $ | 711 | | $ | 907 | | | $ | 204 | | $ | 715 | | $ | 919 | | | 7 | % | (0) | % | 1 | % | | (4) | % | (1) | % | (1) | % | | 7 | % | 5 | % | 5 | % | | (4) | % | 5 | % | 3 | % |
Medication Delivery | 394 | | 211 | | 605 | | | 429 | | 248 | | 677 | | | 425 | | 250 | | 675 | | | (8) | % | (15) | % | (11) | % | | 1 | % | (1) | % | 0 | % | | (8) | % | (10) | % | (9) | % | | 1 | % | 5 | % | 3 | % |
Pharmaceuticals | 208 | | 273 | | 481 | | | 225 | | 303 | | 528 | | | 259 | | 270 | | 529 | | | (8) | % | (10) | % | (9) | % | | (13) | % | 12 | % | (0) | % | | (8) | % | (6) | % | (6) | % | | (13) | % | 19 | % | 3 | % |
Clinical Nutrition | 75 | | 141 | | 216 | | | 77 | | 136 | | 213 | | | 77 | | 138 | | 215 | | | (3) | % | 4 | % | 1 | % | | 0 | % | (1) | % | (1) | % | | (3) | % | 8 | % | 4 | % | | 0 | % | 4 | % | 3 | % |
Advanced Surgery | 94 | | 74 | | 168 | | | 143 | | 88 | | 231 | | | 118 | | 85 | | 203 | | | (34) | % | (16) | % | (27) | % | | 21 | % | 4 | % | 14 | % | | (34) | % | (15) | % | (27) | % | | 21 | % | 11 | % | 17 | % |
Acute Therapies | 72 | | 114 | | 186 | | | 44 | | 88 | | 132 | | | 42 | | 85 | | 127 | | | 64 | % | 30 | % | 41 | % | | 5 | % | 4 | % | 4 | % | | 64 | % | 35 | % | 45 | % | | 5 | % | 9 | % | 8 | % |
BioPharma Solutions | 54 | | 62 | | 116 | | | 54 | | 58 | | 112 | | | 62 | | 49 | | 111 | | | 0 | % | 7 | % | 4 | % | | (13) | % | 18 | % | 1 | % | | 0 | % | 10 | % | 5 | % | | (13) | % | 24 | % | 4 | % |
Other | 21 | | 6 | | 27 | | | 25 | | 9 | | 34 | | | 23 | | 11 | | 34 | | | (16) | % | (33) | % | (21) | % | | 9 | % | (18) | % | 0 | % | | (16) | % | (33) | % | (21) | % | | 9 | % | (9) | % | 3 | % |
Total Baxter | $ | 1,127 | | $ | 1,591 | | $ | 2,718 | | | $ | 1,193 | | $ | 1,641 | | $ | 2,834 | | | $ | 1,210 | | $ | 1,603 | | $ | 2,813 | | | (6) | % | (3) | % | (4) | % | | (1) | % | 2 | % | 1 | % | | (6) | % | 1 | % | (1) | % | | (1) | % | 8 | % | 4 | % |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Quarters Ended March 31, |
| | | | | | | | | | | | | Reported Growth | | Constant Currency Growth |
| 2020 | | 2019 | | 2018 | | 2020 | | 2019 | | 2020 | | 2019 |
| U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total | | U.S. | Int'l | Total |
Net sales by product category: | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Renal Care | $ | 204 | | $ | 666 | | $ | 870 | | | $ | 192 | | $ | 662 | | $ | 854 | | | $ | 196 | | $ | 678 | | $ | 874 | | | 6 | % | 1 | % | 2 | % | | (2) | % | (2) | % | (2) | % | | 6 | % | 4 | % | 4 | % | | (2) | % | 4 | % | 3 | % |
Medication Delivery | 449 | | 229 | | 678 | | | 392 | | 228 | | 620 | | | 421 | | 242 | | 663 | | | 15 | % | 0 | % | 9 | % | | (7) | % | (6) | % | (6) | % | | 15 | % | 5 | % | 11 | % | | (7) | % | 1 | % | (4) | % |
Pharmaceuticals | 220 | | 296 | | 516 | | | 227 | | 278 | | 505 | | | 233 | | 255 | | 488 | | | (3) | % | 6 | % | 2 | % | | (3) | % | 9 | % | 3 | % | | (3) | % | 11 | % | 5 | % | | (3) | % | 17 | % | 8 | % |
Clinical Nutrition | 79 | | 138 | | 217 | | | 74 | | 128 | | 202 | | | 80 | | 142 | | 222 | | | 7 | % | 8 | % | 7 | % | | (8) | % | (10) | % | (9) | % | | 7 | % | 12 | % | 10 | % | | (8) | % | (4) | % | (5) | % |
Advanced Surgery | 137 | | 87 | | 224 | | | 119 | | 79 | | 198 | | | 98 | | 84 | | 182 | | | 15 | % | 10 | % | 13 | % | | 21 | % | (6) | % | 9 | % | | 15 | % | 14 | % | 15 | % | | 21 | % | (1) | % | 11 | % |
Acute Therapies | 60 | | 96 | | 156 | | | 48 | | 81 | | 129 | | | 46 | | 84 | | 130 | | | 25 | % | 19 | % | 21 | % | | 4 | % | (4) | % | (1) | % | | 25 | % | 22 | % | 23 | % | | 4 | % | 5 | % | 5 | % |
BioPharma Solutions | 48 | | 66 | | 114 | | | 50 | | 50 | | 100 | | | 55 | | 47 | | 102 | | | (4) | % | 32 | % | 14 | % | | (9) | % | 6 | % | (2) | % | | (4) | % | 36 | % | 16 | % | | (9) | % | 17 | % | 3 | % |
Other | 20 | | 7 | | 27 | | | 18 | | 12 | | 30 | | | 18 | | 13 | | 31 | | | 11 | % | (42) | % | (10) | % | | 0 | % | (8) | % | (3) | % | | 11 | % | (42) | % | (10) | % | | 0 | % | (8) | % | (3) | % |
Total Baxter | $ | 1,217 | | $ | 1,585 | | $ | 2,802 | | | $ | 1,120 | | $ | 1,518 | | $ | 2,638 | | | $ | 1,147 | | $ | 1,545 | | $ | 2,692 | | | 9 | % | 4 | % | 6 | % | | (2) | % | (2) | % | (2) | % | | 9 | % | 8 | % | 8 | % | | (2) | % | 5 | % | 2 | % |